西藏药业：公司产品新活素被继续纳入国家医保药品目录

Core Viewpoint - The announcement by Tibet Pharmaceutical indicates that its subsidiary, Chengdu Nodi Kang Biopharmaceutical Co., Ltd., has its product, recombinant human brain natriuretic peptide injection (brand name: Xinhuasuan), included in the National Medical Insurance Directory for 2025 and adjusted to the regular directory [1] Group 1 - The product will continue to be covered by the national medical insurance, which is a significant advantage for the company [1] - The adjustment to the regular directory may enhance the product's market accessibility and potential sales [1]